OncoDxRx’s Post

Drug Efficacy Prediction Advances Could Transform Personalized Medicine “Cancer is a network-based disease driven by many interconnected components, but current machine learning and training models for predicting treatment responses don’t always reflect this. Rather than focusing on a few tumor genes or proteins, OncoDxRx’s PGA gene-to-drug technology evaluates the broader biochemical networks or pathways, both tumor and non-tumor microenvironment, vital for cancer killing." One cutting-edge of PGA is the combination of in vitro patient testing and in silico data computation that allows direct patient-to-drug bridging, also thanks to the much-reduced hand-on time and human error in the workflow. This adds to data accuracy, which is also enhanced by the real-time patient testing, by cancer type-specific biomarkers, and by the patient-derived gene expression signature, which proved PGA’s effectiveness in the pilot real-world patient study.  #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

OncoDxRx Moves Forward On PGA and OncoMRD exclusive technologies The PGA (for treatment guidance) combined with OncoMRD (for treatment monitoring) and their evolutions, like precision medicine in current time, will ensure OncoDxRx’s technological exclusivity and capability superiority in the coming decades. OncoMRD will be complementary to PGA and suited to a collaborative or paired testing package. It will incorporate cfmRNA technologies, patient-derived gene signatures, in silico data analytics capacity (with human-in-the-loop), and more. It will be highly versatile and designed to evolve in line with future cancer management. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

Treating the non-responders of precision medicine Modern therapy design and treatment strategies fail to address the key challenge of precision medicine: only a limited percentage of treated patients respond to the precision drugs. Further heart-wrenching weakness of precision medicine is our current inability to predict drug response for those non-responders—following negative biomarker testing results, there may not be enough time to choose an alternative therapy (in the case of fatal cancers). Thus, predicting treatment responses in this desperate population, or defining good candidates for particular treatments, is an urgent and unmet clinical need. The main question is, how can we identify patients who won’t respond to treatment and what is required to tender them potential responders? #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing

In today's unstable malignancy context, in the face of highly dynamic and heterogeneous cancer making our daily lives increasingly uncertain and our future increasingly unpredictable, OncoDxRx is committed to serving our patients. Our mission: improve clinical outcomes and benefit entire patient population by supplying clinicians with the best systems and equipment to meet their needs in all theaters of operation. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

Situational awareness and drug response prediction in cancer treatment is critical to maintaining the therapeutic advantage. Yet the increasing heterogeneity of tumor is constantly challenging this advantage. The evolving of drug resistance, in particular targeted therapy, is significantly contributing to shifting cancer battlefield supremacy. High proliferation and the constant evolution of tumor clones in terms of dynamics, kinetics, immunoediting, immunosuppression and immune escaping increases the level of cancer threat day by day. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing

PGA is perfectly complementary to the existing NGS-based biomarker testing in precision oncology. PGA could benefit those patients "disqualified" by NGS tests, and provide them with alternative therapy options. “In the global markets, PGA is the first and the only drug response prediction test for patient non-responders in the world.” “Today there is no equivalent or similar technology exists. Nothing. Period.” PGA can screen, interrogate, map ALL 700+ existing anticancer drugs to identify the best ones for each patient based on their gene signature. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

Amidst the promises of tailored healthcare lies a formidable obstacle: those patients unresponsive to precision therapy. This critical challenge impedes our ability to harness the full potential of precision medicine, thereby hindering advancements in patient care, clinical research, and drug development. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

Although biomarker tests (or companion diagnostics) offer unprecedented capabilities, they ultimately qualify the minority of patients for precision medicine, while excluding the majority. Precision medicine can no longer solely count on superiority in the field of biomarker testing. PGA can gap-fill biomarker testing to complete test menu, but it is not a substitute or replacement. What is particularly great about PGA is that it provides clinicians with a new dimension of treatment selection. Currently, cancer patients had to be tested to be qualified for precision medicine, and the patient eligibility rate is at low end (around 20-30%) with an average response rate of 20-30%, and you do the math how many patients actually benefit from precision therapy?? With PGA patients now be able to benefit from more drug options than ever before. And because the technology is fitted with patient testing, gene activity detection, data mapping, drug matching and efficacy classification capabilities, as well as interfaces for data fusion, clinicians can be quickly notified of potentially effective drugs winning the decisive time for decision-making. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing

Blood Will Tell: OncoDxRx Scientists Find Potentially Effective Drugs to Non-Responders of Precision Therapy Some patients who receive targeted drugs or immunotherapy experience significant benefit in terms of tumor shrinkage and longer survival as responders — but many do not (ie., non-responders). A new study conducted by OncoDxRx published in Onco (https://lnkd.in/gvKNT9Gn) suggests that measuring overactive genes in the blood could help doctors determine which drugs are most likely to benefit individual non-responders. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy

The innovative medicines we have today only address a small portion of the population and provide no benefit to the majority. As a member of the Dx and Rx industry, what bothers us the most is when "precision medicine" can only be used to help a specific group that others don’t have access to, and this IGNORANCE IS OK! #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD